ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Talking Down Good News

<< Previous

Bullboard Posts

Next >>

Comment by azzymaaon Mar 03, 2022 11:23am

96 Views

Post# 34479248

RE:RE:RE:RE:RE:Talking Down Good News

M101, No idea they were doing this for years. But why put out a statement now? it's funny that the sp goes up to 0.15 cad and dips every singe time there is a pr. you would think after this pr that the sp would go way up or maybe we the investors are the practice mice. gene making half a mil is bs.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks